Subsequently, to further investigate the pro-tumor effects of β-catenin signaling, the β-catenin inhibitor LF3 (17) was applied to treat tumor cells (5-HT pretreatment or TPH1 overexpression), and cell proliferation/migration was detected. Here, TPH1 is linked to neoplasm.